Illustrated Neuropathologic Diagnosis of Alzheimer’s Disease-Reference-Cited by-同舟云学术

Illustrated Neuropathologic Diagnosis of Alzheimer’s Disease

Published:2023-07-12 Issue:3 Volume:15 Page:857-867
ISSN:2035-8377
Container-title:Neurology International
language:en
Short-container-title:Neurology International

Author:

Doher Nicholas¹,Davoudi Vahid²,Magaki Shino³,Townley Ryan A.⁴⁵^ORCID,Haeri Mohammad²⁵^ORCID,Vinters Harry V.³⁶⁷

Affiliation:

1. Department of Neurology, University of Florida, Gainesville, FL 32611, USA

2. Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA

3. Department of Pathology and Laboratory Medicine, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA

4. Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA

5. The University of Kansas Alzheimer’s Disease Research Center, University of Kansas Medical Center, Fairway City, KS 66205, USA

6. Department of Neurology, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA

7. Brain Research Institute, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA

Abstract

As of 2022, the prevalence of Alzheimer’s disease (AD) among individuals aged 65 and older is estimated to be 6.2 million in the United States. This figure is predicted to grow to 13.8 million by 2060. An accurate assessment of neuropathologic changes represents a critical step in understanding the underlying mechanisms in AD. The current method for assessing postmortem Alzheimer’s disease neuropathologic change follows version 11 of the National Alzheimer’s Coordinating Center (NACC) coding guidebook. Ambiguity regarding steps in the ABC scoring method can lead to increased time or inaccuracy in staging AD. We present a concise overview of how this postmortem diagnosis is made and relate it to the evolving understanding of antemortem AD biomarkers.

Funder

University of Kansas

NIH/NIA

Publisher

MDPI AG

Subject

Neurology (clinical)

Link

https://www.mdpi.com/2035-8377/15/3/54/pdf

Reference56 articles.

1. Gessi, S., Poloni, T.E., Negro, G., Varani, K., Pasquini, S., Vincenzi, F., Borea, P.A., and Merighi, S. (2021). A(2A) Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease. Cells, 10.

2. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease;Jack;Alzheimers Dement.,2018

3. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease;Masters;Cold Spring Harb. Perspect. Med.,2012

4. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain;Tapiola;Arch. Neurol.,2009

5. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease;Hansson;Alzheimer’s Res. Ther.,2019